PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer.

Abstract Activation of blood coagulation contributes to cancer progression. Tissue factor pathway inhibitor-1 (TFPI-1) is the main inhibitor of extrinsic coagulation pathway. The aim of this study is to assess the predicting significance of TFPI-1 for thrombotic complication and metastasis in lung cancer patients. Total of 188 non-small cell lung cancer (NSCLC) patients were included in this study. Plasma TFPI-1, D-dimer (D-D), antithrombin (AT), Fibrinogen (Fbg), and coagulating factor VIII activity (FVIII:C) were measured. In NSCLC patients, significantly decreased TFPI-1 and AT and increased D-D, Fbg, and FVIII:C levels were observed, and there was a significant correlation between TFPI-1 and other hemostatic parameters (P < 0.001, resp.). NSCLC patients with deep venous thrombosis (DVT) or metastasis had significantly lower TFPI-1 levels than those without DVT or metastasis (P < 0.01, resp.). Multivariate regression revealed that TFPI-1 acted as a predictor for DVT or tumor metastasis in NSCLC patients [OR: 4.15 or 3.28, P < 0.05, resp.]. The area under ROC curve of TFPI-1 was 0.905 (95% CI, 0.842~0.967) or 0.828 (95% CI, 0.742~0.915) for predicting DVT or metastasis (P < 0.001, resp.). The optimal point of TFPI-1 was 57.7 or 54.3 ng/mL for predicting DVT or metastasis, respectively. Combination of TFPI-1 and D-D measurements can improve the predicting power for DVT or metastasis in NSCLC patients. Our findings suggested that TFPI-1 was a valuable predictor of DVT and tumor metastasis in NSCLC patients.
PMID
Related Publications

Incidence of deep venous thrombosis (DVT) in patients undergoing thoracotomy and changes of hemostasis.

Total tissue factor pathway inhibitor and venous thrombosis. The Longitudinal Investigation of Thromboembolism Etiology.

Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome.

Risk factors for deep vein thrombosis after orthopedic surgery and the diagnostic value of D-dimer.

Analysis of the factors associated with abnormal coagulation and prognosis
 in patients with non-small cell lung cancer.

Authors

Mayor MeshTerms
Keywords
Journal Title biomed research international
Publication Year Start




PMID- 28246607
OWN - NLM
STAT- MEDLINE
DA  - 20170301
DCOM- 20170313
LR  - 20170313
IS  - 2314-6141 (Electronic)
VI  - 2017
DP  - 2017
TI  - Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep
      Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer.
PG  - 8983763
LID - 10.1155/2017/8983763 [doi]
AB  - Activation of blood coagulation contributes to cancer progression. Tissue factor 
      pathway inhibitor-1 (TFPI-1) is the main inhibitor of extrinsic coagulation
      pathway. The aim of this study is to assess the predicting significance of TFPI-1
      for thrombotic complication and metastasis in lung cancer patients. Total of 188 
      non-small cell lung cancer (NSCLC) patients were included in this study. Plasma
      TFPI-1, D-dimer (D-D), antithrombin (AT), Fibrinogen (Fbg), and coagulating
      factor VIII activity (FVIII:C) were measured. In NSCLC patients, significantly
      decreased TFPI-1 and AT and increased D-D, Fbg, and FVIII:C levels were observed,
      and there was a significant correlation between TFPI-1 and other hemostatic
      parameters (P &lt; 0.001, resp.). NSCLC patients with deep venous thrombosis (DVT)
      or metastasis had significantly lower TFPI-1 levels than those without DVT or
      metastasis (P &lt; 0.01, resp.). Multivariate regression revealed that TFPI-1 acted 
      as a predictor for DVT or tumor metastasis in NSCLC patients [OR: 4.15 or 3.28, P
      &lt; 0.05, resp.]. The area under ROC curve of TFPI-1 was 0.905 (95% CI,
      0.842~0.967) or 0.828 (95% CI, 0.742~0.915) for predicting DVT or metastasis (P &lt;
      0.001, resp.). The optimal point of TFPI-1 was 57.7 or 54.3 ng/mL for predicting 
      DVT or metastasis, respectively. Combination of TFPI-1 and D-D measurements can
      improve the predicting power for DVT or metastasis in NSCLC patients. Our
      findings suggested that TFPI-1 was a valuable predictor of DVT and tumor
      metastasis in NSCLC patients.
FAU - Fei, Xianming
AU  - Fei X
AUID- ORCID: 0000-0002-5631-408X
AD  - Center of Laboratory Medicine, Zhejiang Provincial People's Hospital, Hangzhou
      310014, China.
FAU - Wang, Huan
AU  - Wang H
AUID- ORCID: 0000-0001-7042-3306
AD  - Center of Laboratory Medicine, Zhejiang Provincial People's Hospital, Hangzhou
      310014, China.
FAU - Yuan, Wufeng
AU  - Yuan W
AD  - Center of Laboratory Medicine, Zhejiang Provincial People's Hospital, Hangzhou
      310014, China.
FAU - Wo, Mingyi
AU  - Wo M
AUID- ORCID: 0000-0002-2707-518X
AD  - Center of Laboratory Medicine, Zhejiang Provincial People's Hospital, Hangzhou
      310014, China.
FAU - Jiang, Lei
AU  - Jiang L
AUID- ORCID: 0000-0002-2060-6216
AD  - Center of Laboratory Medicine, Zhejiang Provincial People's Hospital, Hangzhou
      310014, China.
LA  - eng
PT  - Journal Article
DEP - 20170126
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Biomarkers)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (Lipoproteins)
RN  - 0 (fibrin fragment D)
RN  - 0 (lipoprotein-associated coagulation inhibitor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Carcinoma, Non-Small-Cell Lung/blood/complications/pathology
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/metabolism
MH  - Humans
MH  - Lipoproteins/*blood
MH  - Logistic Models
MH  - Lung Neoplasms/*blood/complications/*pathology
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Metastasis
MH  - ROC Curve
MH  - Risk Factors
MH  - Venous Thrombosis/blood/*complications/*diagnosis
PMC - PMC5299162
COI - There was no conflict of interests.
EDAT- 2017/03/02 06:00
MHDA- 2017/03/14 06:00
CRDT- 2017/03/02 06:00
PHST- 2016/09/17 [received]
PHST- 2016/12/23 [revised]
PHST- 2017/01/09 [accepted]
AID - 10.1155/2017/8983763 [doi]
PST - ppublish
SO  - Biomed Res Int. 2017;2017:8983763. doi: 10.1155/2017/8983763. Epub 2017 Jan 26.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>